{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,28]],"date-time":"2026-07-28T07:12:50Z","timestamp":1785222770730,"version":"3.55.0"},"reference-count":41,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2017,5,1]],"date-time":"2017-05-01T00:00:00Z","timestamp":1493596800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2017,5,1]],"date-time":"2017-05-01T00:00:00Z","timestamp":1493596800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","jaci-inpractice.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["The Journal of Allergy and Clinical Immunology: In Practice"],"published-print":{"date-parts":[[2017,5]]},"DOI":"10.1016\/j.jaip.2017.03.017","type":"journal-article","created":{"date-parts":[[2017,5,5]],"date-time":"2017-05-05T05:31:52Z","timestamp":1493962312000},"page":"610-615","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":28,"title":["Cardiovascular and Diabetic Medications That Cause Bradykinin-Mediated Angioedema"],"prefix":"10.1016","volume":"5","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-4368-4348","authenticated-orcid":false,"given":"Stephanie N.","family":"Hudey","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emma","family":"Westermann-Clark","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard F.","family":"Lockey","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jaip.2017.03.017_bib1","doi-asserted-by":"crossref","first-page":"979","DOI":"10.1016\/j.crad.2006.06.010","article-title":"Angiotensin-converting enzyme inhibitor-induced visceral angioedema","volume":"61","author":"Marmery","year":"2006","journal-title":"Clin Radiol"},{"key":"10.1016\/j.jaip.2017.03.017_bib2","doi-asserted-by":"crossref","first-page":"842","DOI":"10.1111\/j.1398-9995.2007.01427.x","article-title":"Nonallergic angioedema: role of bradykinin","volume":"62","author":"Bas","year":"2007","journal-title":"Allergy"},{"key":"10.1016\/j.jaip.2017.03.017_bib3","doi-asserted-by":"crossref","first-page":"1057","DOI":"10.1172\/JCI200214211","article-title":"Increased vascular permeability in C1 inhibitor-deficient mice mediated by the bradykinin type 2 receptor","volume":"109","author":"Han","year":"2002","journal-title":"J\u00a0Clin Invest"},{"key":"10.1016\/j.jaip.2017.03.017_bib4","doi-asserted-by":"crossref","first-page":"2161","DOI":"10.1016\/j.molimm.2010.05.010","article-title":"The plasma bradykinin-forming pathways and its interrelationships with complement","volume":"47","author":"Kaplan","year":"2010","journal-title":"Mol Immunol"},{"key":"10.1016\/j.jaip.2017.03.017_bib5","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1016\/j.npep.2015.12.005","article-title":"Role of substance P in the cardiovascular system","volume":"58","author":"Mistrova","year":"2016","journal-title":"Neuropeptides"},{"key":"10.1016\/j.jaip.2017.03.017_bib6","doi-asserted-by":"crossref","first-page":"725","DOI":"10.1016\/j.iac.2006.08.001","article-title":"Angiotensin-converting enzyme inhibitor-associated angioedema","volume":"26","author":"Byrd","year":"2006","journal-title":"Immunol Allergy Clin North Am"},{"key":"10.1016\/j.jaip.2017.03.017_bib7","doi-asserted-by":"crossref","first-page":"1208","DOI":"10.1016\/S0140-6736(07)60242-6","article-title":"Renin-angiotensin system and cardiovascular risk","volume":"369","author":"Schmieder","year":"2007","journal-title":"Lancet"},{"key":"10.1016\/j.jaip.2017.03.017_bib8","doi-asserted-by":"crossref","first-page":"1582","DOI":"10.1001\/2013.jamainternmed.34","article-title":"Comparative risk for angioedema associated with the use of drugs that target the renin-angiotensin-aldosterone system","volume":"172","author":"Toh","year":"2012","journal-title":"Arch Intern Med"},{"key":"10.1016\/j.jaip.2017.03.017_bib9","doi-asserted-by":"crossref","first-page":"1637","DOI":"10.1001\/archinte.165.14.1637","article-title":"Incidence and characteristics of angioedema associated with enalapril","volume":"165","author":"Kostis","year":"2005","journal-title":"Arch Intern Med"},{"key":"10.1016\/j.jaip.2017.03.017_bib10","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1016\/S0009-9236(96)90161-7","article-title":"Black Americans have an increased rate of angiotensin converting enzyme inhibitor-associated angioedema","volume":"60","author":"Brown","year":"1996","journal-title":"Clin Pharmacol Ther"},{"key":"10.1016\/j.jaip.2017.03.017_bib11","doi-asserted-by":"crossref","first-page":"2273","DOI":"10.1097\/HJH.0b013e32834b4b9b","article-title":"Long-term follow-up of 111 patients with angiotensin-converting enzyme inhibitor-related angioedema","volume":"29","author":"Beltrami","year":"2011","journal-title":"J\u00a0Hypertens"},{"key":"10.1016\/j.jaip.2017.03.017_bib12","doi-asserted-by":"crossref","first-page":"643","DOI":"10.1517\/14740338.5.5.643","article-title":"Angiotensin-converting enzyme inhibitor-related angioedema: how to deal with it","volume":"5","author":"Beltrami","year":"2006","journal-title":"Expert Opin Drug Saf"},{"key":"10.1016\/j.jaip.2017.03.017_bib13","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1161\/HYPERTENSIONAHA.109.144600","article-title":"Angiotensin I-converting enzyme inhibitors are allosteric enhancers of kinin B1 and B2 receptor function","volume":"55","author":"Erdos","year":"2010","journal-title":"Hypertension"},{"key":"10.1016\/j.jaip.2017.03.017_bib14","doi-asserted-by":"crossref","first-page":"2088","DOI":"10.1016\/S0140-6736(02)08914-6","article-title":"Aminopeptidase P in individuals with a history of angio-oedema on ACE inhibitors","volume":"359","author":"Adam","year":"2002","journal-title":"Lancet"},{"key":"10.1016\/j.jaip.2017.03.017_bib15","doi-asserted-by":"crossref","first-page":"249","DOI":"10.2217\/pgs.12.206","article-title":"Pharmacogenetics of ACE inhibitor-induced angioedema and cough: a systematic review and meta-analysis","volume":"14","author":"Mahmoudpour","year":"2013","journal-title":"Pharmacogenomics"},{"key":"10.1016\/j.jaip.2017.03.017_bib16","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1161\/01.CIR.0000153269.07762.3B","article-title":"Losartan increases bradykinin levels in hypertensive humans","volume":"111","author":"Campbell","year":"2005","journal-title":"Circulation"},{"key":"10.1016\/j.jaip.2017.03.017_bib17","doi-asserted-by":"crossref","first-page":"1092","DOI":"10.1161\/01.HYP.0000064942.77814.26","article-title":"AT1-receptor antagonism improves endothelial function in coronary artery disease by a bradykinin\/B2-receptor-dependent mechanism","volume":"41","author":"Hornig","year":"2003","journal-title":"Hypertension"},{"key":"10.1016\/j.jaip.2017.03.017_bib18","doi-asserted-by":"crossref","first-page":"1174","DOI":"10.1016\/S0140-6736(08)61242-8","article-title":"Effects of the angiotensin-receptor blocker telmisartan on cardiovascular events in high-risk patients intolerant to angiotensin-converting enzyme inhibitors: a randomised controlled trial","volume":"372","year":"2008","journal-title":"Lancet"},{"key":"10.1016\/j.jaip.2017.03.017_bib19","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1016\/j.amjcard.2012.03.034","article-title":"Meta-analysis of randomized trials of angioedema as an adverse event of renin-angiotensin system inhibitors","volume":"110","author":"Makani","year":"2012","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.jaip.2017.03.017_bib20","doi-asserted-by":"crossref","first-page":"1619","DOI":"10.1002\/lary.25163","article-title":"Treatment of angiotensin receptor blocker-induced angioedema: a case series","volume":"125","author":"Strassen","year":"2015","journal-title":"Laryngoscope"},{"key":"10.1016\/j.jaip.2017.03.017_bib21","doi-asserted-by":"crossref","first-page":"1491","DOI":"10.1016\/j.jaci.2013.03.034","article-title":"A\u00a0focused parameter update: hereditary angioedema, acquired C1 inhibitor deficiency, and angiotensin-converting enzyme inhibitor-associated angioedema","volume":"131","author":"Zuraw","year":"2013","journal-title":"J\u00a0Allergy Clin Immunol"},{"key":"10.1016\/j.jaip.2017.03.017_bib22","doi-asserted-by":"crossref","first-page":"1476","DOI":"10.1016\/j.jacc.2016.05.011","volume":"68","author":"Yancy","year":"2016","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"10.1016\/j.jaip.2017.03.017_bib23","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1016\/S1081-1206(10)60288-8","article-title":"Risk of angioedema with angiotensin receptor blockers in patients with prior angioedema associated with angiotensin-converting enzyme inhibitors: a meta-analysis","volume":"101","author":"Haymore","year":"2008","journal-title":"Ann Allergy Asthma Immunol"},{"key":"10.1016\/j.jaip.2017.03.017_bib24","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1177\/1470320313491997","article-title":"In\u00a0vitro comparison of bradykinin degradation by aliskiren, a renin inhibitor, and an inhibitor of angiotensin-converting enzyme","volume":"16","author":"Joseph","year":"2015","journal-title":"J\u00a0Renin Angiotensin Aldosterone Syst"},{"key":"10.1016\/j.jaip.2017.03.017_bib25","doi-asserted-by":"crossref","first-page":"337","DOI":"10.2147\/TCRM.S23889","article-title":"Pharmacovigilance analysis of adverse event reports for aliskiren hemifumarate, a first-in-class direct renin inhibitor","volume":"7","author":"Ali","year":"2011","journal-title":"Ther Clin Risk Manag"},{"key":"10.1016\/j.jaip.2017.03.017_bib26","doi-asserted-by":"crossref","first-page":"765","DOI":"10.1111\/j.1751-7176.2010.00352.x","article-title":"Safety and tolerability of the direct renin inhibitor aliskiren: a pooled analysis of clinical experience in more than 12,000 patients with hypertension","volume":"12","author":"White","year":"2010","journal-title":"J\u00a0Clin Hypertens (Greenwich)"},{"key":"10.1016\/j.jaip.2017.03.017_bib27","doi-asserted-by":"crossref","first-page":"647","DOI":"10.1111\/jch.12725","article-title":"Two-year outcomes of patients treated with aliskiren under clinical practice conditions: non-interventional prospective study","volume":"18","author":"Zeymer","year":"2016","journal-title":"J\u00a0Clin Hypertens (Greenwich)"},{"key":"10.1016\/j.jaip.2017.03.017_bib28","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1016\/j.beem.2009.03.004","article-title":"Mechanism of action of inhibitors of dipeptidyl-peptidase-4 (DPP-4)","volume":"23","author":"Thornberry","year":"2009","journal-title":"Best Pract Res Clin Endocrinol Metab"},{"key":"10.1016\/j.jaip.2017.03.017_bib29","doi-asserted-by":"crossref","first-page":"516","DOI":"10.1161\/HYPERTENSIONAHA.109.134197","article-title":"Dipeptidyl peptidase-IV inhibitor use associated with increased risk of ACE inhibitor-associated angioedema","volume":"54","author":"Brown","year":"2009","journal-title":"Hypertension"},{"key":"10.1016\/j.jaip.2017.03.017_bib30","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1161\/HYPERTENSIONAHA.107.096552","article-title":"Dipeptidyl peptidase IV in angiotensin-converting enzyme inhibitor associated angioedema","volume":"51","author":"Byrd","year":"2008","journal-title":"Hypertension"},{"key":"10.1016\/j.jaip.2017.03.017_bib31","doi-asserted-by":"crossref","first-page":"436","DOI":"10.1016\/j.anai.2011.02.012","article-title":"DPP-4 inhibitors and angioedema: a cause for concern?","volume":"106","author":"Byrd","year":"2011","journal-title":"Ann Allergy Asthma Immunol"},{"key":"10.1016\/j.jaip.2017.03.017_bib32","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1016\/j.jaci.2007.04.012","article-title":"Dipeptidyl peptidase IV deficiency increases susceptibility to angiotensin-converting enzyme inhibitor-induced peritracheal edema","volume":"120","author":"Byrd","year":"2007","journal-title":"J\u00a0Allergy Clin Immunol"},{"key":"10.1016\/j.jaip.2017.03.017_bib33","doi-asserted-by":"crossref","first-page":"993","DOI":"10.1056\/NEJMoa1409077","article-title":"Angiotensin-neprilysin inhibition versus enalapril in heart failure","volume":"371","author":"McMurray","year":"2014","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jaip.2017.03.017_bib34","doi-asserted-by":"crossref","first-page":"1893","DOI":"10.1056\/NEJMoa032292","article-title":"Valsartan, captopril, or both in myocardial infarction complicated by heart failure, left ventricular dysfunction, or both","volume":"349","author":"Pfeffer","year":"2003","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jaip.2017.03.017_bib35","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1056\/NEJM200001203420301","article-title":"Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. The Heart Outcomes Prevention Evaluation Study Investigators","volume":"342","author":"Yusuf","year":"2000","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jaip.2017.03.017_bib36","doi-asserted-by":"crossref","first-page":"1547","DOI":"10.1056\/NEJMoa0801317","article-title":"Telmisartan, ramipril, or both in patients at high risk for vascular events","volume":"358","author":"ONTARGET Investigators","year":"2008","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jaip.2017.03.017_bib37","doi-asserted-by":"crossref","first-page":"2382","DOI":"10.1210\/en.2008-1360","article-title":"Chronic endothelium-dependent regulation of arterial blood pressure by atrial natriuretic peptide: role of nitric oxide and endothelin-1","volume":"150","author":"Sabrane","year":"2009","journal-title":"Endocrinology"},{"key":"10.1016\/j.jaip.2017.03.017_bib38","doi-asserted-by":"crossref","first-page":"418","DOI":"10.1056\/NEJMoa1312524","article-title":"A\u00a0randomized trial of icatibant in ACE-inhibitor-induced angioedema","volume":"372","author":"Bas","year":"2015","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jaip.2017.03.017_bib39","doi-asserted-by":"crossref","first-page":"278","DOI":"10.1016\/j.annemergmed.2010.03.032","article-title":"Therapeutic efficacy of icatibant in angioedema induced by angiotensin-converting enzyme inhibitors: a case series","volume":"56","author":"Bas","year":"2010","journal-title":"Ann Emerg Med"},{"key":"10.1016\/j.jaip.2017.03.017_bib40","doi-asserted-by":"crossref","first-page":"873","DOI":"10.2146\/ajhp150482","article-title":"Pharmacologic management of angioedema induced by angiotensin-converting enzyme inhibitors","volume":"73","author":"Scalese","year":"2016","journal-title":"Am J Health Syst Pharm"},{"key":"10.1016\/j.jaip.2017.03.017_bib41","doi-asserted-by":"crossref","first-page":"1693","DOI":"10.1016\/S0140-6736(97)09137-X","article-title":"Plasma bradykinin in angio-edema","volume":"351","author":"Nussberger","year":"1998","journal-title":"Lancet"}],"container-title":["The Journal of Allergy and Clinical Immunology: In Practice"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2213219817301885?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2213219817301885?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T05:10:48Z","timestamp":1761973848000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2213219817301885"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,5]]},"references-count":41,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2017,5]]}},"alternative-id":["S2213219817301885"],"URL":"https:\/\/doi.org\/10.1016\/j.jaip.2017.03.017","relation":{},"ISSN":["2213-2198"],"issn-type":[{"value":"2213-2198","type":"print"}],"subject":[],"published":{"date-parts":[[2017,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Cardiovascular and Diabetic Medications That Cause Bradykinin-Mediated Angioedema","name":"articletitle","label":"Article Title"},{"value":"The Journal of Allergy and Clinical Immunology: In Practice","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jaip.2017.03.017","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2017 American Academy of Allergy, Asthma & Immunology","name":"copyright","label":"Copyright"}]}}